NCT06712173View on ClinicalTrials.gov

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

March 31, 2026

Conditions
Peripheral T Cell Lymphoma
Interventions
DRUG

linperlisib and SHR2554

Linperlisib doses were preset at 40mg QD and 60mg QD, while SHR2554 doses were preset at 150mg BID, 200mg BID, and 300mg BID, forming six dose groups in total.

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06712173 - Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) | Biotech Hunter | Biotech Hunter